Trials / Recruiting
RecruitingNCT05670951
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Elgan Pharma Ltd. · Industry
- Sex
- All
- Age
- 1 Day – 5 Days
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELGN-2112 | Human insulin \[rDNA\] |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2025-02-27
- Primary completion
- 2027-11-01
- Completion
- 2029-05-01
- First posted
- 2023-01-04
- Last updated
- 2026-01-23
Locations
1 site across 1 country: Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05670951. Inclusion in this directory is not an endorsement.